# Healthcare & Biotech Industry Benchmarks

## Development Metrics

### Drug Development Timeline
- **Discovery to FDA Approval**: 10-15 years average
- **Pre-clinical**: 3-6 years
- **Clinical Trials (Phase I-III)**: 6-7 years
- **FDA Review**: 10-24 months

### Success Rates
- **Phase I Success Rate**: 70%
- **Phase II Success Rate**: 33%
- **Phase III Success Rate**: 25-30%
- **Overall Probability (Discovery to Approval)**: 5-10%
- **Oncology Success Rate**: 3.4% (lowest)
- **Vaccines/Anti-infectives**: 16% (highest)

## Financial Metrics

### R&D Spending
- **R&D as % of Revenue**: 15-25% (established companies)
- **Early-Stage Biotech**: 80-100% of spending on R&D
- **Cost per Drug Approval**: $1.3B - $2.6B average

### Revenue & Profitability
- **Gross Margin**: 70-90% for approved drugs
- **EBITDA Margin**: 25-40% for profitable companies
- **Operating Margin**: 20-35%

### Market Exclusivity
- **Patent Protection**: 20 years (from filing, ~12-17 years post-approval)
- **Orphan Drug Exclusivity**: 7 years (US)
- **Peak Sales Timeline**: 5-10 years post-launch

## Clinical Trial Metrics

### Trial Costs
- **Phase I**: $1.4M - $6.6M
- **Phase II**: $7M - $19.6M
- **Phase III**: $11.5M - $52.9M
- **Average Total Clinical Cost**: $19M - $80M per drug

### Patient Recruitment
- **Enrollment Rate**: 10-30 patients/month for Phase II
- **Dropout Rate**: 10-30% across all phases
- **Time to Full Enrollment**: 12-36 months

## Valuation Metrics

### Stage-Based Valuations
- **Pre-clinical**: $10M - $50M
- **Phase I**: $50M - $150M
- **Phase II**: $150M - $500M
- **Phase III**: $500M - $2B
- **Approved Drug**: $1B - $10B

### Revenue Multiples
- **EV/Revenue**: 5-15x for growth-stage
-  **EV /EBITDA**: 15-25x

## Funding Benchmarks

### Typical Raise Amounts (2024)
- **Seed/Pre-clinical**: $5M - $20M
- **Series A (Phase I)**: $20M - $50M
- **Series B (Phase II)**: $50M - $100M
- **Series C+ (Phase III)**: $100M - $300M

### Burn Rate
- **Pre-clinical**: $1M - $3M/month
- **Phase I**: $2M - $5M/month
- **Phase II/III**: $5M - $15M/month
- **Runway Expectations**: 18-30 months post-raise

## Regulatory Metrics

### FDA Approval Rates (2020-2024)
- **New Molecular Entities (NMEs)**: 30-50 approvals/year
- **Biologics License Applications (BLAs)**: 15-25 approvals/year
- **First-In-Class Drugs**: 30-40% of approvals
- **Orphan Drugs**: 40-50% of approvals

### Approval Timelines
- **Standard Review**: 10-12 months
- **Priority Review**: 6-8 months
- **Fast Track**: 6 months
- **Breakthrough Therapy**: 4-6 months

## Market Metrics

### Therapeutic Area Growth (CAGR 2024-2030)
- **Oncology**: 8-10%
- **Immunology**: 7-9%
- **Rare Diseases**: 10-12%
- **Gene Therapy**: 25-30%
- **Cell Therapy**: 20-25%

### Geographic Markets
- **US Market Share**: 40-45% of global pharma revenue
- **Europe**: 25-30%
- **Asia-Pacific**: 20-25% (fastest growing)

## Team Structure

### Key Roles (% of headcount)
- **R&D**: 40-50%
- **Clinical Operations**: 20-30%
- **Regulatory Affairs**: 5-10%
- **Commercial/BD**: 10-15%
- **G&A**: 10-15%

---
*Sources: FDA Databases, NIH Clinical Trials Data, BIS Research Healthcare Reports, Grand View Research Biotech Market Analysis*
